Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,963 | -5,701 | -27,029 | -20,376 | -14,376 |
| Depreciation Amortization | -331 | -128 | -743 | -644 | -429 |
| Accounts receivable | -9 | N/A | 562 | 577 | 588 |
| Accounts payable and accrued liabilities | -312 | 84 | -451 | -572 | 122 |
| Other Working Capital | -326 | 219 | -3,594 | -3,203 | -2,573 |
| Other Operating Activity | 303 | 369 | 7,320 | 5,450 | 3,334 |
| Operating Cash Flow | $-10,638 | $-5,157 | $-23,935 | $-18,768 | $-13,334 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -17,511 | -7 | 15,575 | 17,893 | 347 |
| PPE Investments | N/A | N/A | -34 | -34 | -34 |
| Investing Cash Flow | $-17,511 | $-7 | $15,541 | $17,859 | $313 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 30,370 | N/A | 7,855 | 7,855 | 7,520 |
| Financing Cash Flow | $30,370 | $N/A | $7,855 | $7,855 | $7,520 |
| Beginning Cash Position | 12,620 | 12,620 | 13,159 | 13,159 | 13,159 |
| End Cash Position | 14,841 | 7,456 | 12,620 | 20,105 | 7,658 |
| Net Cash Flow | $2,221 | $-5,164 | $-539 | $6,946 | $-5,501 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,638 | -5,157 | -23,935 | -18,768 | -13,334 |
| Capital Expenditure | N/A | N/A | -34 | -34 | -34 |
| Free Cash Flow | -10,638 | -5,157 | -23,969 | -18,802 | -13,368 |